We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes.
Status note Injectable nimodipine formulation for improved management of hypotension in hospitalized aSAH patients. Pivotal Phase 3 STRIVE-ON randomized safety trial vs nimodipine oral capsules completed enrollment September 2024; NDA submitted to FDA under 505(b)(2); FDA issued a Complete Response Letter and the company is addressing CRL items toward NDA resubmission.
GTx-101
Stage not disclosed · Terminated
Indications
postherpetic neuralgia (PHN)(Stage not disclosed)
Status note Discontinued June 2026 per strategic decision to focus on GTx-104; company impaired the capitalized IPR&D carrying value of GTx-101 and GTx-102 ($13.533M combined). Company notes it may seek to maximize value via licensing or sale.
GTx-102
Stage not disclosed · Terminated
Indications
Ataxia Telangiectasia(Stage not disclosed)
Status note Discontinued June 2026 per strategic decision to focus on GTx-104; company impaired the capitalized IPR&D carrying value of GTx-101 and GTx-102 ($13.533M combined). Company notes it may seek to maximize value via licensing or sale.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.